FDA Clears Update of AI-Enabled Imaging Contour Models
Updates to Contour ProtegeAI 4.0 reportedly include enhanced algorithms for radiation oncology segmentation and molecular radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated version of Contour ProtegeAI® 4.0 (MIM Software), a platform that provides automated deep learning segmentation for organs at risk (OARs).
Contour ProtegeAI 4.0 offers improved algorithms for radiation oncology as well as improvements for molecular radiotherapy, according to MIM Software.
“Over the past several months, the MIM Software team has worked hard to focus this new version on improving our contouring performance,” noted Jay Obman, a product manager at MIM Software, Inc. “The initial testing has shown a good improvement in our overall contour quality, and I’m excited for our users to reap the benefits of those improvements as well as some new contours we’ve added.”
The company adds that the software facilitates standardized, efficient workflows and provides automated preparation for physician target volume (PTV) contouring. Contour ProtegeAI 4.0 also integrates with Eclipse™, RayStation®, Monaco® and Pinnacle, according to MIM Software.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
